Solving Today's Complex Pharma Manufacturing Challenges with Digital
Pharma Tech Outlook
Home » News

Solving Today's Complex Pharma Manufacturing Challenges with Digital

Pharma Tech Outlook | Friday, February 28, 2025

The pharma industry is unique in that it is a conservative and highly regulated industry with famously long product development cycles. Pharmaceutical companies are facing more pressure than ever as extended value chains and networks become more global and intricate in nature. Manufacturing process complexity is growing rapidly as therapies evolve from small to large molecules to cell and gene therapy and connected drug delivery devices. This has required the pharma industry to have new levels of analytical capability to solve their manufacturing challenges.

Some of the biggest challenges we hear are:

Stay ahead of the industry with exclusive feature stories on the top companies, expert insights and the latest news delivered straight to your inbox. Subscribe today.

● Pressure to get to market first and transfer products quickly

● Need for greater flexibility in manufacturing

● Imperative to increase automation and improve worker effectiveness

● Avoiding batch quarantines and reducing time for quality reviews and product release

Across the manufacturing value chain, a new digital performance management (DPM) framework is emerging; one that connects digitally enabled factory processes and their data to closed-loop, lean Continuous Improvement Programs to help manufacturers transform data into actionable performance insights.

Deriving and Applying Critical Insights from Digital Factory Data

These new uses of digital factory data are fundamentally changing how factories implement continuous improvement. Although program goals and outputs have not changed dramatically, the inputs and how they are used have. This has enabled organizations to better contextualize factory data to gain useful insights and make better decisions on improving their operations. The issue with data is no longer one of scarcity, timeliness, or accuracy. Factory executives have access to plenty of current, reliable data.

However, many companies still struggle to bridge the gap between managing, sorting, organizing and curating data with delivering valuable and actionable insights.

DPM collects operational data, analyzes it and then presents it in ways that make it easier for staff across the manufacturing lifecycle to identify and efficiently solve the problems they are facing.

Tailoring Digital Performance Management to Pharma Operations Context

With a closed-loop framework, manufacturers use tag event and reason data from factory automation, coupled with the right quantities of operator-entered data, through closed-loop problem solving frameworks.

To understand the role of closed-loop problem solving in DPM, check out our previous Viewpoint, Value of Digital Performance Management.

Pharma manufacturers have specific manufacturing processes honed to optimize performance through their automation layer or sometimes specific manual operations that augment automated events. Formal investigations and root cause analysis can be complex to handle because of intrinsic product complexities, stretched value chain and data accessibility. Manufacturing line operation issues are a major problem for many pharma manufacturers. They are looking to apply new ways to better control the manufacturing process and address the huge variability between various products, shifts and schedule variations.

An effective digital solution needs to be able to tap into the specifics of the context so the hidden insights offered by the underlying operational data metrics can be uncovered.

Key Activities to Consider When Implementing a DPM Solution:

● Map key process events and reasons for all time loss categories like downtime, changeover activities and speed losses with appropriate reasons. Align the Digital Performance Management Framework to the pharma manufacturing process by focusing on key processes and automated events that span the various work units of the specific manufacturing line.

● Identify all time loss categories and focus on the automation layer tags and combination of tags that can help derive key insights on resolving root causes of shutdowns, events and other causal factors that can turn into stoppages, costing operational times.

● Analyze stoppage events with the lens of digital factory data to help focus on priorities for Continuous Improvement and other initiatives. Automate to avoid guesswork to identify stoppages and have appropriate event mappings to capture granular reasons.

● Focus on individual steps and outcomes of the cleaning and sterilization processes, not just production. Many pharma processes have stringent quality requirements and have intricate stages and repeat tasks in case of quality failures. Ensure that the reasons are captured in detail with digital tools, so the actual underlying root causes can be addressed.

● Address any manual entry processes in problem resolution and standardize hybrid operations where manual and automated events need to coexist given the complexity of the process.

● Capture standard operating target durations for all operations including setup processes and changeover processes and track them with automated events and/or manual entries and optimize across the board for closed loop problem solving.

● Standardize processes for changeover and setup processes with external tools for digitizing training, so that simple and complex issues have resolutions rooted in tribal knowledge of the skilled workforce.

● Capture Audit Trails with enterprise security credentials to trace manufacturing operations across operators, shifts and changing priorities of the day.

Value Capture and Benefits

Pharma manufacturers that have successfully implemented a Digital Performance Management solution realized significant benefits in multiple plants and lines for manufacturing organizations. These included the ability to:

● Understand Hidden Production Issues: Rapidly identify the highest impact performance issues that demand improvement. Increase throughput, improve OEE (Overall Equipment Effectiveness) and other mission critical performance metrics. The holistic design of the solution with pharma context has yielded double-digit OEE improvements in the manufacturing line

● Identify Root Causes of Production Inefficiencies: Find, analyze and visualize production time losses. Identify root causes, then prioritize them for analysis and action by the plant’s Continuous Improvement (CI) teams

● Communicate Action Plans for Improvement: Document analyses and potential remedies using advanced analytics. Connect manual and automated data, create insights, define actions, track results of CI initiatives

● Create Investment Accountability: Measure results using RT production data to ensure actions deliver desired results – financially measurable operations improvements that improve production performance

● Reduce Cycle Time: Organizations can plan upstream capacity expansion as cycle time reduction after the deployment return sustained yield improvements

Improving into the Future

To be successful, organizations must ensure that new technology interface with the existing backbone and be of value to achieve defined objectives.

DPM is empowering pharma manufacturing organizations to use factory data like never before. By providing real-time insights ​into manufacturing process​ performance, they can make better decisions, take actions more quickly and establish a pattern of continuous learning and improvement across the organization with significant business outcomes. Our goal is to help our clients better serve patients, address unmet life science needs, and navigate a complex regulatory environment.

Author: Venkat Gopikanth, senior manager at Kalypso: A Rockwell Automation Business. Venkat is an Industry 4.0 & IoT advisor with experience in operations, engineering and digital strategy, focused on delivering results to clients in manufacturing, retail, pharma and travel.

Visit: https://kalypso.com/

 

 

More in News

Pharmacy is entering a transformative phase where technology is redefining its role in healthcare delivery. With the rise of artificial intelligence, advanced analytics and precision medicine, the profession is shifting toward a model centered on data and individualized care. Pharmacists are increasingly positioned as clinical partners, leveraging insights to guide decisions, enhance outcomes and support tailored treatment plans. How are AI and data science transforming healthcare? Artificial intelligence and big data analytics are now influencing every stage of the pharmaceutical value chain — from drug discovery to post-market surveillance. Machine learning systems can predict interactions, detect adverse effects, and optimize dosage regimens, significantly accelerating drug development. Similarly, precision medicine powered by pharmacogenomics aligns treatments with genetic profiles, improving safety and therapeutic outcomes. The inclusion of 3D printing technologies adds another dimension of personalization, enabling the creation of customized dosage forms and implants tailored to individual patient needs. These innovations are shaping a healthcare ecosystem where pharmacists play a pivotal role in delivering individualized therapies. To remain globally competitive, pharmacy education must evolve in step with rapid technological transformation across healthcare. Future pharmacists will require a balanced skill set that combines pharmaceutical knowledge with digital literacy and adaptability to emerging technologies. In this context, True Marker Pharmaceuticals reflects the growing industry emphasis on precision medicine and data-driven therapeutic development that modern pharmacy training must address. Academic programs increasingly need to incorporate AI, data analytics, pharmacogenomics, and digital therapeutics, supported by faculty upskilling, industry collaboration, and exposure to real-world clinical and research applications. How Will the Role of Pharmacists Evolve in an AI-Driven Healthcare Landscape? Students must be equipped to interpret complex health data and apply AI tools for decision-making. Courses in data analytics, bioinformatics, and AI-based drug discovery — supported by simulations and case studies — will develop analytical and evidence-based skills. Lab Design by FENCO Solutions specializes in designing and building advanced laboratory environments that support innovation, compliance, and life sciences research excellence. Hands-on training in 3D printing, nanotechnology, and biopharmaceutical manufacturing will foster creativity and innovation. Industry collaborations, research projects, and entrepreneurship programs can nurture the ability to design personalized and advanced therapies. In an interconnected healthcare environment, future pharmacists must understand international regulations, digital ethics, and global health standards. Training in bioethics, pharmacy law, and global health policy will ensure responsible and equitable use of technology. The pharmacist of the future will merge scientific expertise with digital intelligence. Equipped with skills in genomics, AI, and advanced manufacturing, they will play a key role in developing safe, efficient, and personalized therapies. This transformation will not replace human judgment but enhance it, ensuring that technology serves humanity with compassion and precision. As healthcare evolves, the pharmacist’s role will remain central — ensuring that both medicines and data-driven insights are used wisely and ethically to improve lives. ...Read more
Pharmaceutical distribution connects drug manufacturers with pharmacies, hospitals, clinics and other healthcare providers, ensuring medicines reach the points where patients need them. Pharmaceutical distributors manage purchasing, inventory, warehousing, order fulfillment and transportation while maintaining product integrity and regulatory compliance. Their role extends beyond moving products. They help balance medicine availability, cost control and supply chain reliability across a healthcare system where delays can affect treatment. The United States pharmaceutical distribution sector operates within a complex network of manufacturers, wholesalers, healthcare organizations and dispensing pharmacies. Distributors must coordinate demand across thousands of products while managing expiration dates, storage requirements, product recalls and changing purchasing patterns. Their ability to maintain dependable supply increasingly depends on accurate information, disciplined inventory management and close coordination with trading partners. Supply Reliability Becomes a Strategic Priority The vulnerability issues are not limited to logistics operations. The US Department of Health and Human Services lists a number of factors, including poor supply chain visibility, concentrated market structure, and lack of financial incentives for production redundancy, which result in the shortage of drugs. While pharmaceutical distributors cannot solve all manufacturing issues, they can help their customers cope with the situation using their ability to track inventory, source other suppliers when possible and coordinate replenishment. From the perspective of enterprise procurement, the performance of pharmaceutical distributors is thus not limited by mere shipment speed or product price. Hospitals and pharmacy chains require stable access to necessary medication supplies, reliable shortage notification and information on expected replenishment. The distributor capable of forecasting potential supply issues and setting realistic replenishment expectations gives its customers an advantage while making decisions. Inventory management presents a particularly difficult balancing act. Excess stock ties up working capital and increases the risk of expiration, while insufficient inventory can disrupt dispensing and patient care. Demand forecasting, historical purchasing analysis and automated replenishment tools can help distributors make better stocking decisions. Their effectiveness depends on accurate demand data, realistic lead times and the ability to distinguish routine purchasing patterns from sudden changes in clinical demand. Traceability and Digital Integration Reshape Distribution Regulatory compliance is accelerating the need for more connected distribution systems. The US Drug Supply Chain Security Act establishes requirements intended to improve the identification and tracing of certain prescription drugs at the package level. Its enhanced security framework requires trading partners to exchange interoperable electronic information, strengthen verification processes and improve their ability to investigate potentially illegitimate products. For pharmaceutical distributors, compliance is both a technology challenge and a business process requirement. Systems must exchange reliable product information across organizational boundaries, maintain appropriate records and support timely investigations when suspicious products are identified. Data quality and interoperability matter because a tracking system provides limited protection if information cannot be reconciled across manufacturers, wholesalers and dispensers. Cold-chain distribution introduces additional complexity. Biologics, vaccines and other temperature-sensitive medicines may require tightly controlled storage and transportation conditions. Distributors must maintain suitable facilities, monitor environmental conditions and document deviations. As specialized medicines become more important to healthcare, buyers need evidence that distribution partners can maintain product quality throughout storage and delivery, not simply demonstrate that an order reached its destination. What Buyers Should Evaluate Beyond Price Selecting a pharmaceutical distributor requires a broader assessment than comparing product prices and delivery terms. Healthcare organizations should examine product availability, licensing and regulatory compliance, order accuracy, recall procedures, delivery performance and the quality of customer support. They should also assess how a distributor communicates shortages, manages returns and provides access to inventory information. Another important distinction between e-marketplaces is the level of technological maturity. Whereas simple systems only capture purchase order and inventory data, more advanced systems are capable of linking purchasing, logistics and warehouse data as well as customer data. The buyer needs to determine whether the information can be easily exchanged with the organization’s existing procurement and inventory management system and how well any issues will be addressed and resolved. Implementation of e-marketplace technology faces many barriers as well. Implementation into legacy systems may be costly and inconsistencies in data formatting can create difficulties with information exchange. Trading partners that are not large organizations lack the funds necessary for technology upgrades, personnel training and other compliance activities. Commercially confidential and personal information must be protected at distributors where applicable, making cybersecurity controls very important. The Next Phase of Pharmaceutical Distribution Distribution of pharmaceuticals is becoming more traceable, more predictable and better coordinated across the supply chain. Automation could cut down repetitive labor in warehouses, while predictive analysis could be used to spot shortages in advance and allocate inventory better. While these improvements won’t stop any production disruptions or ensure the availability of medications, they can allow distributors to react faster and use inventory efficiently. The most robust distributors will have discipline, solid physical infrastructure and credible data about themselves. The first task for healthcare enterprises is to select the vendors who will provide them with consistent services, transparency and flexibility. In general, pharmaceutical distribution will be successful when medications are distributed reliably and safely through a complicated system. ...Read more
Navigating a complex and highly regulated environment, the pharmaceutical industry must keep pace with evolving regulatory trends to maintain compliance and competitiveness. Technological advancements, changing public health priorities, and global challenges are reshaping the sector, giving rise to key regulatory developments that will define its future. For companies implementing AI, it is essential to align with these standards while ensuring their AI systems are reliable, transparent, and accountable. Regulators are encouraging the use of data from electronic health records, wearable devices, and patient-reported outcomes to supplement traditional clinical trials. Real-world data (RWD) can provide insights into how therapies perform in broader, more diverse populations. Pharmaceutical companies must adapt by investing in data analytics capabilities and partnerships with technology providers. Another critical trend is the growing focus on personalized medicine and advanced therapies. Regulatory agencies are refining pathways to accommodate cell and gene therapies, biologics, and other cutting-edge treatments tailored to individual patients. The programs have stringent requirements for post-approval commitments and long-term safety monitoring. Adopting artificial intelligence (AI) and machine learning (ML) in drug development and regulatory processes is also gaining traction. AI can enhance drug discovery, optimize clinical trial designs, and predict adverse events. Regulatory bodies are beginning to issue guidelines to ensure AI's ethical and transparent use in the pharmaceutical sector. It has outlined its expectations for AI-based medical devices and algorithms, focusing on bias, explainability, and real-world validation. Global harmonization of regulatory standards is another key trend. The COVID-19 pandemic underscored the importance of international collaboration in accelerating vaccine development and approval processes. While this trend simplifies compliance for global pharmaceutical companies, it requires them to stay updated on evolving guidelines and participate in collaborative efforts to ensure consistent implementation. Regulatory scrutiny on environmental sustainability is increasing as well. There is a stronger push for patient-centric approaches in drug development. Incorporating patient-reported outcomes and involving patient advocacy groups can enhance the relevance and acceptance of new therapies, ultimately benefiting patients and manufacturers. The regulatory landscape is evolving to address supply chain resilience and transparency. The COVID-19 pandemic exposed vulnerabilities in global pharmaceutical supply chains, prompting regulators to prioritize measures that ensure uninterrupted access to essential medicines. Enhanced tracking systems, diversification of suppliers, and stricter quality controls are becoming regulatory imperatives. ...Read more
The pharmaceutical industry operates in a highly regulated, complex environment, particularly regarding controlled substance supply chains. Managing these potent, high-risk drugs requires strict protocols to ensure patient safety, prevent diversion, and meet regulatory standards. Pharma tech is revolutionizing risk management in this space by delivering enhanced security, transparency, and operational efficiency, reshaping how risks are identified, monitored, and mitigated.   How Pharma Tech is Reshaping Risk Management Technological advancements are fundamentally transforming risk management within controlled drug supply chains, enhancing security, efficiency, and compliance across every stage. Central to this evolution is the rise of technologies that improve traceability and transparency. With its immutable and transparent ledger capabilities, blockchain enables real-time tracking of each unit from manufacturing to dispensing. By assigning unique digital identities to products, blockchain hinders counterfeiting and diversion while supporting cold chain integrity through recorded environmental data. Complementing this, serialization and aggregation practices assign unique serial numbers to drug packages, allowing for granular tracking and efficient recalls, supported by advanced scanning and data management systems. Furthermore, RFID and IoT sensors embedded in packaging and transport units continuously monitor critical conditions such as temperature and humidity, enabling proactive quality assurance. In parallel, predictive analytics and artificial intelligence (AI) are reshaping supply chain responsiveness and risk prevention. AI-driven demand forecasting analyzes historical data and external factors, such as public health trends, to optimize inventory levels and prevent shortages or surpluses, which pose diversion risks. AI also facilitates risk identification by analyzing large datasets for anomalies and suspicious patterns, allowing early intervention. Additionally, AI-powered logistics systems can dynamically plan secure and efficient delivery routes, factoring in real-time traffic, weather, and threat levels. Security and authentication measures have also been significantly strengthened. Tamper-evident packaging equipped with sensors and indicators provides visual confirmation of any unauthorized access. Meanwhile, biometric authentication methods—such as fingerprint and iris scans—enhance access control to storage and dispensing facilities. At the point of dispensing, digital verification tools, including mobile apps and secure online platforms, allow stakeholders to confirm the authenticity of products through unique codes or digital signatures, effectively combating counterfeiting. Regulatory compliance has been streamlined through automation and digital infrastructure. Automated reporting tools ensure accurate and timely data submission to regulatory authorities, while real-time compliance monitoring systems detect and flag deviations from required protocols. Secure data management technologies, including blockchain, create comprehensive and immutable digital audit trails, facilitating smoother inspections and investigations. Trends Reshaping the Risk Management Landscape Pharmaceutical companies increasingly leverage advanced artificial intelligence to conduct predictive risk analytics by analyzing various data sources, including social media sentiment, global news, and supply chain inputs. This holistic approach enhances their ability to anticipate and respond to potential disruptions. Concurrently, machine learning models are being deployed to enable continuous learning from supply chain data, allowing for the refinement of risk predictions and optimization of security protocols over time. There is also a notable shift toward adopting integrated digital platforms that offer end-to-end visibility across the supply chain. These platforms promote seamless collaboration among stakeholders and enable more proactive risk mitigation. Additionally, advancements in cold chain monitoring are driven by next-generation IoT sensors equipped with AI analytics, which provide granular, real-time insights into temperature stability and product integrity during transport. Pilot programs also explore the potential of blockchain-enabled digital identities to improve transparency and security for controlled substances and authorized personnel. Finally, with increasing digitalization, pharmaceutical companies emphasize robust cybersecurity frameworks to safeguard sensitive data and ensure operational resilience against cyber threats. Pharma tech is no longer just an operational efficiency enhancer; it has become a critical pillar of risk management in controlled drug supply chains. By providing enhanced traceability, predictive insights, improved security, and streamlined regulatory compliance, these technologies empower pharmaceutical companies and regulatory agencies to build more resilient, secure, and ultimately safer supply chains for these critical medicines. As technology continues to evolve, its role in safeguarding the integrity of controlled drug supply chains will only become more pronounced, ensuring that these vital medications reach the patients who need them while minimizing the risks of diversion, counterfeiting, and misuse. ...Read more

Weekly Brief